CYP cynata therapeutics limited

As the AGM approaches, I urge everyone here who is a shareholder...

  1. 275 Posts.
    lightbulb Created with Sketch. 267

    As the AGM approaches, I urge everyone here who is a shareholder to carefully consider your vote on the remuneration report. As a shareholder, I believe it’s our responsibility to ensure that Cynata’s executive pay aligns with company performance and is transparent. Unfortunately, Cynata falls short in two critical areas:

    1. Lack of Alignment with Performance: Executive remuneration should reflect Cynata’s performance and progress. However, expected trial result announcements continue to be delayed, no partnership has been secured, and our cash position is weakening. With the increased likelihood of raising funds through new equity placements, long-term shareholders face further dilution.

    2. Insufficient Transparency of KPIs: Shareholders have never had visibility into the Key Performance Indicators (KPIs) set for our executives, yet bonuses are continually paid out for meeting these undisclosed targets. Without transparency, shareholders cannot confirm whether incentives are genuinely performance-based or aligned with long-term value creation.

    For these reasons, I encourage you to vote against the remuneration report and hold our leadership accountable for delivering real results and transparency.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
0.010(6.25%)
Mkt cap ! $38.41M
Open High Low Value Volume
16.0¢ 17.5¢ 16.0¢ $45.60K 278.0K

Buyers (Bids)

No. Vol. Price($)
4 62994 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 107450 3
View Market Depth
Last trade - 15.17pm 18/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.